Population Pharmacokinetic Analysis in Drug Development

This white paper discusses the application of population pharmacokinetic (PopPK) analysis in early drug development efforts. It highlights how PopPK has become an essential tool for clinical pharmacology experts, particularly in analyzing data from human subjects. The document outlines the transition from traditional pharmacokinetic (PK) methods, which relied on healthy volunteers, to PopPK techniques that accommodate dosage adjustments for various patient subgroups, including the elderly and those with compromised liver function. It explains the mathematical modeling behind PopPK, detailing how individual PK parameters relate to population averages and how variability among subjects is quantified. The paper also illustrates the use of PopPK in analyzing non-clinical and early clinical data, emphasizing its role in optimizing drug development processes and improving therapeutic monitoring. By integrating PopPK techniques, researchers can extract valuable insights that guide dosage recommendations and enhance the understanding of drug behavior across different populations.